Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Testosterone | 53 | 2021 | 2420 | 3.620 |
Why?
|
Muscle Strength | 21 | 2019 | 592 | 1.880 |
Why?
|
Body Composition | 30 | 2018 | 2401 | 1.790 |
Why?
|
Muscle, Skeletal | 40 | 2019 | 4931 | 1.740 |
Why?
|
Physical Fitness | 8 | 2020 | 733 | 1.580 |
Why?
|
Exercise Test | 18 | 2020 | 2074 | 1.340 |
Why?
|
Hormone Replacement Therapy | 9 | 2018 | 745 | 1.280 |
Why?
|
Mobility Limitation | 9 | 2020 | 409 | 1.260 |
Why?
|
Physical Endurance | 13 | 2015 | 370 | 1.230 |
Why?
|
Oxygen Consumption | 14 | 2018 | 1869 | 1.170 |
Why?
|
Androgens | 16 | 2020 | 1281 | 1.160 |
Why?
|
Muscle Fatigue | 4 | 2008 | 83 | 0.810 |
Why?
|
Exercise Therapy | 5 | 2009 | 906 | 0.720 |
Why?
|
Aging | 14 | 2020 | 8664 | 0.620 |
Why?
|
Hypogonadism | 6 | 2018 | 799 | 0.610 |
Why?
|
Renal Dialysis | 7 | 2015 | 1786 | 0.600 |
Why?
|
Geriatric Assessment | 2 | 2020 | 1372 | 0.550 |
Why?
|
Disease Transmission, Infectious | 1 | 2020 | 547 | 0.510 |
Why?
|
Double-Blind Method | 29 | 2021 | 12026 | 0.480 |
Why?
|
Accidental Falls | 5 | 2020 | 1062 | 0.410 |
Why?
|
Resistance Training | 4 | 2015 | 165 | 0.400 |
Why?
|
Cross Infection | 1 | 2020 | 1416 | 0.400 |
Why?
|
Dietary Proteins | 4 | 2021 | 963 | 0.390 |
Why?
|
Anabolic Agents | 4 | 2011 | 247 | 0.380 |
Why?
|
Renal Insufficiency | 2 | 2007 | 804 | 0.370 |
Why?
|
Occupational Health | 2 | 2014 | 809 | 0.360 |
Why?
|
HIV Wasting Syndrome | 3 | 2005 | 97 | 0.360 |
Why?
|
Motor Activity | 5 | 2014 | 2714 | 0.360 |
Why?
|
Exercise | 14 | 2019 | 5615 | 0.350 |
Why?
|
Dentate Gyrus | 2 | 2020 | 160 | 0.340 |
Why?
|
Growth Substances | 2 | 2006 | 784 | 0.300 |
Why?
|
Somatomedins | 1 | 2007 | 192 | 0.300 |
Why?
|
Sarcopenia | 3 | 2019 | 368 | 0.290 |
Why?
|
Leuprolide | 2 | 2008 | 321 | 0.290 |
Why?
|
Doping in Sports | 2 | 2009 | 63 | 0.280 |
Why?
|
Quadriceps Muscle | 1 | 2007 | 144 | 0.280 |
Why?
|
Male | 92 | 2021 | 350118 | 0.270 |
Why?
|
Nandrolone | 1 | 2005 | 17 | 0.270 |
Why?
|
Death, Sudden, Cardiac | 1 | 2014 | 1541 | 0.260 |
Why?
|
Myostatin | 5 | 2011 | 124 | 0.260 |
Why?
|
Aged | 52 | 2021 | 163280 | 0.260 |
Why?
|
Weight Lifting | 4 | 2013 | 131 | 0.260 |
Why?
|
Leg | 3 | 2008 | 1116 | 0.250 |
Why?
|
Androgen Antagonists | 2 | 2012 | 1377 | 0.250 |
Why?
|
Atherosclerosis | 2 | 2018 | 3445 | 0.250 |
Why?
|
Receptors, Androgen | 5 | 2016 | 1058 | 0.250 |
Why?
|
Kidney Failure, Chronic | 5 | 2011 | 2538 | 0.240 |
Why?
|
Lung Diseases, Obstructive | 3 | 2010 | 316 | 0.240 |
Why?
|
Human Growth Hormone | 2 | 2009 | 683 | 0.240 |
Why?
|
Sexual Behavior | 6 | 2016 | 2057 | 0.240 |
Why?
|
Transforming Growth Factor beta | 4 | 2007 | 2007 | 0.230 |
Why?
|
Administration, Cutaneous | 5 | 2020 | 711 | 0.230 |
Why?
|
Physical Exertion | 7 | 2014 | 695 | 0.230 |
Why?
|
5-alpha Reductase Inhibitors | 2 | 2016 | 107 | 0.220 |
Why?
|
Muscle Contraction | 4 | 2008 | 1240 | 0.220 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 5 | 2014 | 3047 | 0.220 |
Why?
|
CA3 Region, Hippocampal | 2 | 2020 | 56 | 0.220 |
Why?
|
Walking | 5 | 2018 | 1180 | 0.220 |
Why?
|
Gels | 3 | 2020 | 427 | 0.210 |
Why?
|
Placebos | 6 | 2018 | 1676 | 0.200 |
Why?
|
Gonadal Steroid Hormones | 4 | 2014 | 712 | 0.200 |
Why?
|
Fatigue | 5 | 2018 | 1531 | 0.200 |
Why?
|
Health Promotion | 1 | 2014 | 2205 | 0.200 |
Why?
|
Absorptiometry, Photon | 8 | 2021 | 1725 | 0.200 |
Why?
|
Hysterectomy | 2 | 2019 | 927 | 0.190 |
Why?
|
Humans | 103 | 2021 | 744343 | 0.190 |
Why?
|
Exercise Tolerance | 4 | 2009 | 770 | 0.190 |
Why?
|
Lung | 2 | 2018 | 9856 | 0.190 |
Why?
|
Activities of Daily Living | 2 | 2021 | 2418 | 0.180 |
Why?
|
Muscle Fibers, Skeletal | 3 | 2011 | 555 | 0.180 |
Why?
|
Middle Aged | 49 | 2020 | 213383 | 0.180 |
Why?
|
3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 2 | 2017 | 62 | 0.180 |
Why?
|
Lactates | 6 | 2007 | 432 | 0.170 |
Why?
|
RNA, Messenger | 6 | 2011 | 13033 | 0.170 |
Why?
|
Body Mass Index | 8 | 2017 | 12720 | 0.170 |
Why?
|
Discrimination Learning | 1 | 2020 | 280 | 0.170 |
Why?
|
Sexuality | 2 | 2014 | 174 | 0.160 |
Why?
|
Nurse's Role | 1 | 2020 | 209 | 0.160 |
Why?
|
Insulin-Like Growth Factor I | 6 | 2007 | 2015 | 0.160 |
Why?
|
Fitness Centers | 2 | 2014 | 12 | 0.160 |
Why?
|
Weight Loss | 6 | 2009 | 2622 | 0.150 |
Why?
|
Agrin | 1 | 2017 | 68 | 0.150 |
Why?
|
Dose-Response Relationship, Drug | 10 | 2019 | 10943 | 0.150 |
Why?
|
Geriatric Nursing | 1 | 2017 | 39 | 0.150 |
Why?
|
Asymptomatic Infections | 1 | 2018 | 128 | 0.150 |
Why?
|
Lung Volume Measurements | 1 | 2018 | 378 | 0.150 |
Why?
|
Blood Glucose | 5 | 2021 | 6256 | 0.150 |
Why?
|
Patient Care Management | 1 | 2020 | 306 | 0.140 |
Why?
|
Risk Assessment | 7 | 2020 | 23338 | 0.140 |
Why?
|
Adult | 48 | 2019 | 214055 | 0.140 |
Why?
|
Health Status | 5 | 2018 | 4034 | 0.140 |
Why?
|
Task Performance and Analysis | 1 | 2020 | 780 | 0.140 |
Why?
|
Intra-Abdominal Fat | 1 | 2021 | 591 | 0.140 |
Why?
|
Finasteride | 1 | 2016 | 90 | 0.130 |
Why?
|
Body Weight | 7 | 2014 | 4669 | 0.130 |
Why?
|
Independent Living | 4 | 2020 | 568 | 0.130 |
Why?
|
Aged, 80 and over | 16 | 2020 | 57776 | 0.130 |
Why?
|
Wounds and Injuries | 2 | 2018 | 2400 | 0.130 |
Why?
|
Receptor, IGF Type 1 | 3 | 2006 | 390 | 0.130 |
Why?
|
Sexual Dysfunctions, Psychological | 1 | 2016 | 187 | 0.130 |
Why?
|
Muscle Weakness | 2 | 2012 | 413 | 0.120 |
Why?
|
Pulmonary Gas Exchange | 4 | 2008 | 382 | 0.120 |
Why?
|
Skinfold Thickness | 1 | 2014 | 162 | 0.120 |
Why?
|
Body Temperature | 4 | 2013 | 777 | 0.120 |
Why?
|
Patients | 1 | 2020 | 900 | 0.120 |
Why?
|
Luteinizing Hormone | 4 | 2004 | 869 | 0.110 |
Why?
|
HIV Infections | 7 | 2019 | 16718 | 0.110 |
Why?
|
Amphetamine-Related Disorders | 1 | 2013 | 67 | 0.110 |
Why?
|
Hypopituitarism | 1 | 2014 | 254 | 0.110 |
Why?
|
Alopecia | 1 | 2016 | 382 | 0.110 |
Why?
|
Oxygen Inhalation Therapy | 2 | 2010 | 367 | 0.110 |
Why?
|
Forced Expiratory Volume | 2 | 2014 | 1743 | 0.100 |
Why?
|
Azasteroids | 1 | 2012 | 38 | 0.100 |
Why?
|
Protective Devices | 1 | 2012 | 71 | 0.100 |
Why?
|
Residential Treatment | 1 | 2013 | 111 | 0.100 |
Why?
|
Capillaries | 1 | 2015 | 773 | 0.100 |
Why?
|
Body Temperature Regulation | 1 | 2013 | 252 | 0.100 |
Why?
|
Treatment Outcome | 12 | 2020 | 63114 | 0.100 |
Why?
|
Female | 40 | 2020 | 380194 | 0.100 |
Why?
|
Vital Capacity | 1 | 2014 | 925 | 0.100 |
Why?
|
Methamphetamine | 1 | 2013 | 154 | 0.100 |
Why?
|
Energy Intake | 3 | 2017 | 2148 | 0.100 |
Why?
|
Psychomotor Performance | 1 | 2019 | 1901 | 0.100 |
Why?
|
Spleen | 1 | 2017 | 2362 | 0.100 |
Why?
|
Nitric Oxide Synthase Type I | 1 | 2011 | 170 | 0.100 |
Why?
|
Fires | 1 | 2012 | 173 | 0.100 |
Why?
|
Hand Strength | 1 | 2014 | 448 | 0.100 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2020 | 9959 | 0.090 |
Why?
|
Wasting Syndrome | 2 | 2009 | 101 | 0.090 |
Why?
|
Gonadotropin-Releasing Hormone | 3 | 2008 | 1205 | 0.090 |
Why?
|
Reproducibility of Results | 6 | 2020 | 19905 | 0.090 |
Why?
|
Muscle Proteins | 4 | 2012 | 1159 | 0.090 |
Why?
|
Anaerobic Threshold | 2 | 2008 | 52 | 0.090 |
Why?
|
Clinical Trials as Topic | 4 | 2018 | 7913 | 0.090 |
Why?
|
Habits | 1 | 2010 | 139 | 0.090 |
Why?
|
Oxygen | 3 | 2010 | 4189 | 0.090 |
Why?
|
Nitric Oxide Synthase Type II | 1 | 2011 | 534 | 0.090 |
Why?
|
Memory | 1 | 2019 | 2174 | 0.090 |
Why?
|
Cholestenone 5 alpha-Reductase | 1 | 2009 | 21 | 0.090 |
Why?
|
Muscle Fibers, Slow-Twitch | 2 | 2006 | 49 | 0.090 |
Why?
|
Insulin Resistance | 2 | 2018 | 3864 | 0.080 |
Why?
|
Community Health Services | 1 | 2014 | 650 | 0.080 |
Why?
|
Muscle Fibers, Fast-Twitch | 2 | 2006 | 69 | 0.080 |
Why?
|
Breath Tests | 1 | 2010 | 280 | 0.080 |
Why?
|
Lactic Acid | 6 | 2008 | 1133 | 0.080 |
Why?
|
Prostatic Neoplasms | 1 | 2012 | 11124 | 0.080 |
Why?
|
Nitric Oxide Synthase Type III | 1 | 2011 | 689 | 0.080 |
Why?
|
Quality of Life | 7 | 2018 | 12804 | 0.080 |
Why?
|
Patient Participation | 1 | 2017 | 1457 | 0.080 |
Why?
|
Research Design | 3 | 2017 | 5987 | 0.080 |
Why?
|
Affect | 4 | 2018 | 1476 | 0.080 |
Why?
|
Nerve Net | 1 | 2019 | 2174 | 0.080 |
Why?
|
Insulin-Like Growth Factor II | 2 | 2006 | 271 | 0.070 |
Why?
|
Reproduction | 1 | 2012 | 668 | 0.070 |
Why?
|
Growth Hormone | 1 | 2009 | 705 | 0.070 |
Why?
|
Hippocampus | 1 | 2019 | 3675 | 0.070 |
Why?
|
Organ Size | 4 | 2019 | 2252 | 0.070 |
Why?
|
Ergometry | 2 | 2004 | 17 | 0.070 |
Why?
|
HIV | 2 | 2018 | 1604 | 0.070 |
Why?
|
Peptide Fragments | 2 | 2017 | 5097 | 0.070 |
Why?
|
Sex Hormone-Binding Globulin | 3 | 2004 | 548 | 0.070 |
Why?
|
Glycogen | 1 | 2006 | 260 | 0.070 |
Why?
|
Internationality | 1 | 2011 | 1003 | 0.070 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 1 | 2006 | 216 | 0.070 |
Why?
|
Mitochondria, Muscle | 1 | 2006 | 171 | 0.070 |
Why?
|
Libido | 2 | 2016 | 121 | 0.060 |
Why?
|
Cholesterol | 1 | 2014 | 2917 | 0.060 |
Why?
|
Substance-Related Disorders | 1 | 2001 | 4258 | 0.060 |
Why?
|
Androstenedione | 1 | 2004 | 131 | 0.060 |
Why?
|
Catheterization | 1 | 2010 | 1470 | 0.060 |
Why?
|
Heart Rate | 2 | 2013 | 4091 | 0.060 |
Why?
|
Disease Progression | 2 | 2018 | 13284 | 0.060 |
Why?
|
Cognition | 2 | 2016 | 6770 | 0.060 |
Why?
|
Anti-Retroviral Agents | 1 | 2013 | 1715 | 0.060 |
Why?
|
Time Factors | 4 | 2018 | 40075 | 0.060 |
Why?
|
Biopsy | 3 | 2018 | 6756 | 0.060 |
Why?
|
Mental Health | 1 | 2018 | 3019 | 0.060 |
Why?
|
Interleukin-6 | 1 | 2013 | 3200 | 0.060 |
Why?
|
Adipose Tissue | 3 | 2005 | 3279 | 0.060 |
Why?
|
Age Factors | 4 | 2008 | 18370 | 0.060 |
Why?
|
Oxymetholone | 1 | 2002 | 9 | 0.060 |
Why?
|
Appetite | 1 | 2005 | 243 | 0.060 |
Why?
|
Young Adult | 11 | 2019 | 56430 | 0.060 |
Why?
|
Muscles | 2 | 1998 | 1614 | 0.050 |
Why?
|
Sexual Dysfunction, Physiological | 2 | 2016 | 360 | 0.050 |
Why?
|
Reference Values | 5 | 2016 | 4982 | 0.050 |
Why?
|
Chronic Disease | 2 | 2009 | 9146 | 0.050 |
Why?
|
Adiposity | 1 | 2012 | 1807 | 0.050 |
Why?
|
Consensus | 1 | 2011 | 2959 | 0.050 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2013 | 4420 | 0.050 |
Why?
|
Intubation, Intratracheal | 1 | 2010 | 1364 | 0.050 |
Why?
|
Risk Factors | 5 | 2020 | 72290 | 0.050 |
Why?
|
Kidney | 1 | 2017 | 7186 | 0.050 |
Why?
|
Liver | 1 | 2017 | 7474 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 9 | 2020 | 35421 | 0.050 |
Why?
|
Body Water | 1 | 2001 | 343 | 0.050 |
Why?
|
Pigmentation Disorders | 1 | 2001 | 101 | 0.050 |
Why?
|
Respiratory Function Tests | 1 | 2004 | 1616 | 0.040 |
Why?
|
Nutritional Physiological Phenomena | 1 | 2001 | 370 | 0.040 |
Why?
|
Metabolic Diseases | 1 | 2006 | 658 | 0.040 |
Why?
|
Work | 1 | 1980 | 191 | 0.040 |
Why?
|
Muscle Development | 1 | 2001 | 271 | 0.040 |
Why?
|
Glucocorticoids | 1 | 2009 | 2107 | 0.040 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 4751 | 0.040 |
Why?
|
Depressive Disorder, Major | 1 | 2016 | 4644 | 0.040 |
Why?
|
Pelvic Floor | 1 | 2019 | 138 | 0.040 |
Why?
|
Menopause, Premature | 1 | 2019 | 132 | 0.040 |
Why?
|
Inflammation | 1 | 2018 | 10638 | 0.040 |
Why?
|
Physical Education and Training | 2 | 2009 | 106 | 0.040 |
Why?
|
Blood Pressure | 1 | 2014 | 8554 | 0.040 |
Why?
|
Rejuvenation | 1 | 2019 | 91 | 0.040 |
Why?
|
Cross-Sectional Studies | 4 | 2014 | 25043 | 0.040 |
Why?
|
Hair | 1 | 2001 | 483 | 0.040 |
Why?
|
Anger | 2 | 1996 | 402 | 0.040 |
Why?
|
Sex Factors | 4 | 2020 | 10397 | 0.040 |
Why?
|
Carbon Dioxide | 2 | 2002 | 1150 | 0.040 |
Why?
|
Adolescent | 10 | 2019 | 85781 | 0.040 |
Why?
|
Patient Compliance | 3 | 2014 | 2684 | 0.040 |
Why?
|
Central Nervous System Diseases | 1 | 2001 | 518 | 0.030 |
Why?
|
Models, Biological | 3 | 2008 | 9583 | 0.030 |
Why?
|
Receptor, IGF Type 2 | 2 | 2006 | 35 | 0.030 |
Why?
|
Lipids | 4 | 2012 | 3305 | 0.030 |
Why?
|
Fatty Acids | 1 | 2003 | 1809 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 3870 | 0.030 |
Why?
|
Viremia | 1 | 2018 | 736 | 0.030 |
Why?
|
Organ Specificity | 2 | 2012 | 2008 | 0.030 |
Why?
|
Forecasting | 2 | 2019 | 2951 | 0.030 |
Why?
|
Risk Management | 1 | 2017 | 571 | 0.030 |
Why?
|
Prostate | 2 | 2012 | 1774 | 0.030 |
Why?
|
Pelvis | 1 | 2018 | 730 | 0.030 |
Why?
|
Severity of Illness Index | 2 | 2014 | 15540 | 0.030 |
Why?
|
Calorimetry, Indirect | 1 | 2013 | 183 | 0.030 |
Why?
|
Sebum | 1 | 2012 | 16 | 0.030 |
Why?
|
Regression Analysis | 3 | 2004 | 6459 | 0.030 |
Why?
|
Ovariectomy | 1 | 2014 | 661 | 0.030 |
Why?
|
Erectile Dysfunction | 1 | 2014 | 461 | 0.020 |
Why?
|
Analysis of Variance | 2 | 2012 | 6365 | 0.020 |
Why?
|
Hematocrit | 1 | 2012 | 636 | 0.020 |
Why?
|
Dyspnea | 2 | 2014 | 1303 | 0.020 |
Why?
|
Obesity Hypoventilation Syndrome | 1 | 2010 | 17 | 0.020 |
Why?
|
Respiration | 3 | 2002 | 1653 | 0.020 |
Why?
|
Thigh | 2 | 2003 | 247 | 0.020 |
Why?
|
Cold Temperature | 1 | 2013 | 772 | 0.020 |
Why?
|
Oxidation-Reduction | 1 | 2015 | 2187 | 0.020 |
Why?
|
Gene Expression | 2 | 2016 | 7799 | 0.020 |
Why?
|
Gait | 1 | 2014 | 793 | 0.020 |
Why?
|
Depression | 2 | 2020 | 7766 | 0.020 |
Why?
|
Life Style | 3 | 2006 | 3835 | 0.020 |
Why?
|
Kinetics | 3 | 2004 | 6473 | 0.020 |
Why?
|
Arousal | 1 | 2014 | 1165 | 0.020 |
Why?
|
Insulin-Like Growth Factor Binding Protein 4 | 1 | 2007 | 26 | 0.020 |
Why?
|
Differential Threshold | 1 | 2007 | 80 | 0.020 |
Why?
|
Insulin | 2 | 2018 | 6580 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2013 | 2559 | 0.020 |
Why?
|
SKP Cullin F-Box Protein Ligases | 1 | 2007 | 177 | 0.020 |
Why?
|
Health Education | 1 | 2013 | 1056 | 0.020 |
Why?
|
Carbohydrate Metabolism | 1 | 2007 | 264 | 0.020 |
Why?
|
Anxiety | 1 | 2020 | 4297 | 0.020 |
Why?
|
Prostate-Specific Antigen | 1 | 2016 | 2494 | 0.020 |
Why?
|
Pilot Projects | 1 | 2019 | 8324 | 0.020 |
Why?
|
Myosin Heavy Chains | 1 | 2007 | 414 | 0.020 |
Why?
|
Hyperlipidemias | 1 | 2010 | 789 | 0.020 |
Why?
|
Postmenopause | 1 | 2014 | 2461 | 0.020 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2018 | 3327 | 0.020 |
Why?
|
Cardiovascular Diseases | 1 | 2010 | 15165 | 0.020 |
Why?
|
California | 1 | 2008 | 1402 | 0.020 |
Why?
|
Central Nervous System Stimulants | 1 | 2013 | 1148 | 0.020 |
Why?
|
Administration, Oral | 1 | 2012 | 3913 | 0.010 |
Why?
|
Primary Health Care | 1 | 2020 | 4558 | 0.010 |
Why?
|
Coronary Vessels | 1 | 2015 | 3107 | 0.010 |
Why?
|
Electrocardiography | 1 | 2017 | 6442 | 0.010 |
Why?
|
Energy Metabolism | 1 | 1995 | 2899 | 0.010 |
Why?
|
Neuropsychological Tests | 1 | 2016 | 6993 | 0.010 |
Why?
|
Behavior | 2 | 1996 | 561 | 0.010 |
Why?
|
Menstruation | 1 | 2004 | 302 | 0.010 |
Why?
|
Needs Assessment | 1 | 2009 | 1147 | 0.010 |
Why?
|
Respiratory Dead Space | 1 | 2002 | 30 | 0.010 |
Why?
|
Health Status Indicators | 1 | 2008 | 969 | 0.010 |
Why?
|
Sports | 1 | 2009 | 688 | 0.010 |
Why?
|
3T3 Cells | 1 | 2004 | 1101 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2013 | 5078 | 0.010 |
Why?
|
Hypertension | 2 | 2015 | 8480 | 0.010 |
Why?
|
Linear Models | 2 | 2007 | 5952 | 0.010 |
Why?
|
Protein Isoforms | 1 | 2007 | 1730 | 0.010 |
Why?
|
Animals | 3 | 2011 | 168757 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2008 | 2886 | 0.010 |
Why?
|
Anatomy, Cross-Sectional | 1 | 2002 | 141 | 0.010 |
Why?
|
Calcium | 1 | 2015 | 5756 | 0.010 |
Why?
|
Muscular Atrophy | 1 | 2005 | 349 | 0.010 |
Why?
|
Incidence | 1 | 2020 | 20947 | 0.010 |
Why?
|
Respiratory Physiological Phenomena | 1 | 2002 | 188 | 0.010 |
Why?
|
Osmolar Concentration | 1 | 2003 | 683 | 0.010 |
Why?
|
Equipment Design | 1 | 2010 | 3582 | 0.010 |
Why?
|
Gene Expression Regulation | 2 | 2011 | 12072 | 0.010 |
Why?
|
Health Behavior | 1 | 2013 | 2636 | 0.010 |
Why?
|
Analgesics, Opioid | 1 | 2017 | 3674 | 0.010 |
Why?
|
Obesity | 2 | 2015 | 12745 | 0.010 |
Why?
|
Lower Extremity | 1 | 2008 | 1158 | 0.010 |
Why?
|
Boston | 1 | 2013 | 9313 | 0.010 |
Why?
|
Hospitalization | 1 | 2020 | 10262 | 0.010 |
Why?
|
Tidal Volume | 1 | 2002 | 490 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2018 | 10180 | 0.010 |
Why?
|
Drug Design | 1 | 2006 | 1076 | 0.010 |
Why?
|
Hypertrophy | 1 | 2002 | 569 | 0.010 |
Why?
|
Methods | 1 | 1980 | 1129 | 0.010 |
Why?
|
Research | 1 | 2008 | 1999 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2010 | 6538 | 0.010 |
Why?
|
Nutrition Assessment | 1 | 2002 | 723 | 0.010 |
Why?
|
Comorbidity | 1 | 2013 | 10388 | 0.010 |
Why?
|
Melanins | 1 | 2001 | 289 | 0.010 |
Why?
|
Actins | 1 | 2006 | 2121 | 0.010 |
Why?
|
Hormones | 1 | 2003 | 889 | 0.010 |
Why?
|
Reference Standards | 1 | 2002 | 1025 | 0.010 |
Why?
|
Sickness Impact Profile | 1 | 2000 | 302 | 0.010 |
Why?
|
Dihydrotestosterone | 1 | 1998 | 190 | 0.010 |
Why?
|
Air | 1 | 1998 | 182 | 0.010 |
Why?
|
Ligands | 1 | 2004 | 3282 | 0.010 |
Why?
|
Melanocytes | 1 | 2001 | 515 | 0.010 |
Why?
|
Keratinocytes | 1 | 2001 | 798 | 0.010 |
Why?
|
Gonadotropins, Pituitary | 1 | 1996 | 73 | 0.010 |
Why?
|
Fasting | 1 | 2002 | 1593 | 0.010 |
Why?
|
Follicle Stimulating Hormone | 1 | 1998 | 744 | 0.010 |
Why?
|
Cohort Studies | 1 | 2019 | 40561 | 0.010 |
Why?
|
Logistic Models | 1 | 2010 | 13408 | 0.010 |
Why?
|
Data Collection | 1 | 2004 | 3341 | 0.010 |
Why?
|
Injections, Intramuscular | 1 | 1996 | 552 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2003 | 4933 | 0.010 |
Why?
|
Norepinephrine | 2 | 1987 | 909 | 0.010 |
Why?
|
Syndrome | 1 | 2001 | 3251 | 0.010 |
Why?
|
United States | 2 | 2014 | 69872 | 0.010 |
Why?
|
Single-Blind Method | 1 | 1998 | 1590 | 0.010 |
Why?
|
Quality Assurance, Health Care | 1 | 2004 | 2212 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2011 | 21746 | 0.010 |
Why?
|
Epinephrine | 2 | 1987 | 792 | 0.010 |
Why?
|
Prospective Studies | 1 | 2018 | 53288 | 0.010 |
Why?
|
Cross-Over Studies | 1 | 1998 | 2029 | 0.010 |
Why?
|
Sex Characteristics | 1 | 2002 | 2585 | 0.010 |
Why?
|
Treatment Failure | 1 | 1998 | 2618 | 0.010 |
Why?
|
Polymorphism, Genetic | 1 | 2003 | 4328 | 0.010 |
Why?
|
Models, Statistical | 1 | 2006 | 5102 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2009 | 39050 | 0.000 |
Why?
|
Skin | 1 | 2001 | 4364 | 0.000 |
Why?
|
Cell Differentiation | 1 | 2004 | 11483 | 0.000 |
Why?
|
Emotions | 1 | 1998 | 2661 | 0.000 |
Why?
|
Mice | 1 | 2004 | 81183 | 0.000 |
Why?
|